2,868 Natera, Inc. $NTRA Shares Sold by CenterBook Partners LP

Posted by Brenda Bartman on Nov 11th, 2026

CenterBook Partners LP decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 56.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,231 shares of the medical research company’s stock after selling 2,868 shares during the period. CenterBook Partners LP’s holdings in Natera were worth $922,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Trust Co. of Vermont bought a new stake in shares of Natera in the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC acquired a new stake in Natera during the second quarter valued at approximately $30,000. Continuum Advisory LLC bought a new stake in Natera during the second quarter worth approximately $33,000. Rakuten Securities Inc. bought a new stake in Natera during the second quarter worth approximately $35,000. Finally, Burkett Financial Services LLC bought a new stake in Natera during the third quarter worth approximately $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the transaction, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the transaction, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 47,056 shares of company stock worth $17,760,989. Corporate insiders own 5.05% of the company’s stock.

Natera Trading Down 2.6%

Shares of NTRA opened at $311.98 on Wednesday. The company has a 50-day moving average of $379.93 and a two-hundred day moving average of $270.42. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The firm had revenue of $793.98 million for the quarter, compared to analyst estimates of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The firm’s revenue was up 34.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.64) EPS. Equities analysts forecast that Natera, Inc. will post -1.20 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. UBS Group lifted their price target on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Rothschild & Co Redburn started coverage on Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective for the company. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Piper Sandler restated an “overweight” rating and issued a $363.50 target price on shares of Natera in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Get Our Latest Research Report on NTRA

More Natera News

Here are the key news stories impacting Natera this week:

Positive Sentiment: Third-quarter revenue rose 34.1% to about $794 million, beating estimates, and Natera raised its 2026 sales outlook as test volumes—particularly oncology testing—accelerated. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
Positive Sentiment: Management highlighted a long-term goal of $6 billion in revenue by 2029, supported by Signatera growth, broader reimbursement and continued investment. Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
Positive Sentiment: Natera is collaborating with Incyte on a Phase 2 colorectal cancer trial, which could support its oncology testing business, though the commercial impact will depend on trial results and adoption. Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
Neutral Sentiment: A report listed short interest at zero shares as of November 10, a figure that does not indicate meaningful short positioning; the report’s description of a significant increase appears inconsistent with that number.
Negative Sentiment: Despite the revenue beat, Natera’s quarterly loss of $0.42 per share was wider than the $0.28 loss analysts expected, highlighting ongoing profitability concerns. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
Negative Sentiment: Analysts cut price targets, including Robert W. Baird’s reduction to $403 from $458, while maintaining an Outperform rating. JPMorgan also reportedly lowered its target, adding a cautious note despite the improved outlook. Robert W. Baird Stock Recommendations Natera Stock Gets Price Target Cut from JPMorgan Chase & Co.

Natera Profile

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.